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i.org/1Japanese subjects and evaluated the effect of alirocumab at 3 doses (50, 75, 150 mg) on low-
density lipoprotein cholesterol (LDL-C) reduction in patients with primary hypercholes-
terolemia on atorvastatin. A randomized, single ascending-dose study of alirocumab (100,
150, 250, or 300 mg) or placebo (3:1 ratio), administered subcutaneously, was conducted in
32 healthy Japanese men. The phase 2, randomized, double-blind, placebo-controlled,
parallel-group study was performed in patients with primary hypercholesterolemia (deﬁned
as calculated LDL-C ‡100 mg/dl [2.6 mmol/l]) who were on a stable dose of atorvastatin
(5 to 20 mg). Patients were randomized to alirocumab (50, 75, or 150 mg) or placebo (in
single 1.0-ml injection volumes) administered every 2 weeks (Q2W) for 12 weeks; the pri-
mary outcome was the mean percent change in calculated LDL-C from baseline to week 12.
Single subcutaneous administration of alirocumab in healthy subjects was well tolerated
over 15 weeks and resulted in highest mean percent reductions in LDL-C from baseline of
approximately 40% to 60%. In the multiple-dose study, least-square mean (SE) changes in
calculated LDL-C concentrations from baseline to week 12 were L54.8% (3.1%) for alir-
ocumab 50 mg,L62.3% (3.1%) for alirocumab 75 mg, andL71.7% (3.1%) for alirocumab
150 mg, with a least-square mean (SE) difference versus placebo of L52.2%
(4.3%), L59.6% (4.3%), and L69.1% (4.3%), respectively (all p <0.0001). In conclusion,
alirocumab was well tolerated and signiﬁcantly reduced LDL-C concentrations in Japanese
patients with primary hypercholesterolemia on atorvastatin.  2016 The Author(s).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;118:56e63)The risk of coronary artery disease and all-cause mor-
tality rises in association with increasing concentrations of
low-density lipoprotein cholesterol (LDL-C) in both Japa-
nese and Western populations.1e6 The NIPPON DATA80
trial7 and the Japan Lipid Intervention Trial (J-LIT)3
emphasized the importance of risk factors, including dys-
lipidemia, hypertension, diabetes, smoking, and obesity, in
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0.1016/j.amjcard.2016.04.011Consequently, alongside improvements in lifestyle, the
Japan Atherosclerosis Society has recommended serum
LDL-C management goals, which vary according to the
presence of various coronary artery disease risk factors
(Supplementary Table 1).8e10 A 2002 study from the Japan
Lipid Assessment Program (J-LAP),11 involving 24,048
patients with primary hyperlipidemia on statin treatment,
showed that the total cholesterol goals recommended in the
Japan Atherosclerosis Society 2002 guidelines8 were ach-
ieved in only 53.1% of patients and the LDL-C goals in
63.4%. Furthermore, the rate of achievement was substan-
tially higher (61%) in patients at low-to-moderate risk
compared with those at high risk (45%). A more recent
retrospective study,12 based on data collected from 2009 to
2012, indicated no improvement in achievement of lipid
goals in secondary prevention, with 38% of treated Japa-
nese patients at high cardiovascular risk failing to attain the
2012 Japan Atherosclerosis Society10 target of <100 mg/dl
(2.6 mmol/l) for LDL-C. Alirocumab is a fully human
monoclonal antibody against proprotein convertase subtili-
sin/kexin 9 (PCSK9). In phase 2 and 3 studies conducted
primarily in Western populations, alirocumab as mono-
therapy or in combination with other lipid-lowering thera-
pies (LLT) reduced LDL-C concentrations by 40% to
73%.13e21 We report here the results from initial studies of
alirocumab in Japanese subjects. The principal objective
of the phase 1 study was to assess the safety and tolerabilityccess article
4.0/).
www.ajconline.org
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subjects. The phase 2 study was designed to assess the ef-
fect of alirocumab at 3 different doses (50, 75, and 150 mg)
administered every 2 weeks (Q2W) for 12 weeks on LDL-C
reduction in patients with primary hypercholesterolemia
who were taking a stable dose of atorvastatin. The effect of
alirocumab on other lipid parameters, as well as its safety
and tolerability, was also evaluated.
Methods
We conducted 2 separate randomized placebo-controlled
trials with alirocumab. The ﬁrst one was a single ascending-
dose study in healthy Japanese men. The second one was a
multiple-dose study in patients with primary hypercholes-
terolemia on a background of stable atorvastatin 5 to 20 mg/
day therapy. Both studies were conducted according to the
Declaration of Helsinki and the International Conference on
Harmonization guidelines for Good Clinical Practice. The
institutional review board and ethics committee at each
center approved the protocol. All participants gave written
informed consent.
In the phase 1, single-dose, 15-week (106 days) study, 32
healthy men aged 20e65 years, with a body weight from
50.0 to 95.0 kg, a body mass index from 18.0 to 30.0 kg/m2,
and serum LDL-C concentration >100 mg/dl (2.6 mmol/l)
were enrolled at 1 site. None of the subjects had been taking
or were currently on medications. The full entry criteria,
drug administration schedule, and outcome measures are
detailed in Supplementary Text 1. In each sequential dose
cohort of 100, 150, 250, and 300 mg, 8 subjects were
randomly allocated (3:1) to receive a single dose of alir-
ocumab (6 subjects) or placebo (2 subjects). Study drug was
administered subcutaneously into the abdomen by research
staff. Subjects were required to remain at the research
facility for observation for 5 days. Blood was drawn for
evaluation at baseline and at days 1, 2, 3, 4, 8, 11, 15, 22,
29, 43, 64, and 106 (Supplementary Figure 1). A physical
examination, assessment of vital signs, electrocardiography,
blood tests, and serum antidrug antibody level measurement
were also performed. Use of nonstudy drugs was not
permitted during the study unless prespeciﬁed or if required,
in which case the drug name, dose, duration, and indication
were recorded.
The multidose study was a multicenter, randomized,
double-blind, placebo-controlled, parallel-group, phase 2
trial. The study population comprised patients aged 20 to
75 years with primary hypercholesterolemia, deﬁned as a
calculated LDL-C concentration of 100 mg/dl (2.6 mmol/l),
who were treated with atorvastatin at a stable dose of 5 to
20 mg (the dose range approved in Japan for primary hy-
percholesterolemia) for 6 weeks before the screening visit.
The full entry criteria are detailed in Supplementary Text 2.
The study comprised a screening period with 2 options
described in the following, depending on whether the pa-
tient had been on stable atorvastatin therapy for 6 weeks
beforehand, followed by a 12-week double-blind interven-
tion period, and an 8-week off-treatment follow-up period
(Supplementary Figure 1). The screening period was of
1-week duration in patients who had been receiving ator-
vastatin at a stable dose of 5 to 20 mg/day for 6 weeksbefore screening. Patients on LLT other than atorvastatin,
who were not taking a stable dose of atorvastatin at 5 to
20 mg/day, or who were drug naïve, were asked to start
atorvastatin (5 to 20 mg/day; and stop other LLT, if taking)
6 weeks before screening. The choice of atorvastatin dose in
these patients was left at the investigator’s discretion.
During the 12-week intervention period, patients were
randomized to 1 of 3 doses of alirocumab (50, 75, or
150 mg Q2W) or placebo Q2W, all in single 1.0-ml doses
administered subcutaneously by research staff into the
abdomen. Randomization was stratiﬁed by the dose of
atorvastatin received at randomization (<10 or 10 mg).
Patients were instructed to remain on a stable dose of
atorvastatin and on a stable diet (Japan Atherosclerosis
Society Guidelines for Prevention of Atherosclerotic Car-
diovascular Diseases or equivalent)10 throughout the study,
from screening onward. The primary outcome measure was
the mean percent change in calculated LDL-C from baseline
to week 12, analyzed in the modiﬁed intent-to-treat popu-
lation, which included all patients who underwent
randomization and who had a primary end point that could
be evaluated. The secondary outcome measures were the
absolute change in calculated LDL-C from baseline to week
12; the proportion of patients achieving LDL-C <100
(2.6 mmol/l) or <70 mg/dl (1.8 mmol/l) at week 12; and
percent and absolute changes in total cholesterol, high-
density lipoprotein cholesterol (HDL-C), triglycerides, and
noneHDL-C from baseline to week 12. The safety outcome
measures were the occurrence of adverse events, vital signs,
electrocardiographic variables, and laboratory ﬁndings
(hematology, serum biochemistry), which were assessed at
baseline, then every 2 weeks up to the end of the double-
blind treatment period. Off-treatment follow-up visits,
including safety outcome measures, were performed at
weeks 16 and 20. The treatment-emergent adverse event
observation period was deﬁned as the time from the ﬁrst
injection of study medication to the last injection plus
70 days (10 weeks).
In the single-dose study, we estimated that 6 subjects
per dose group would provide 80% power to detect a
treatment difference of 30% (SD 15%) versus placebo in
percent change from baseline in LDL-C when comparing
each dose with placebo and using a 2-sided t test and
signiﬁcance level of 5% (not adjusted for multiple com-
parisons). Absolute and percent changes from baseline
for each pharmacodynamic variable were analyzed using
an analysis of covariance (ANCOVA) model, with the
dose group as the ﬁxed effect and the relevant baseline
value as a covariate. Differences between dose groups
and the placebo group, 95% conﬁdence intervals, and p
values for comparison between the treatment group and
the placebo group were obtained within the framework of
ANCOVA.
In the multiple-dose study, we estimated that 25 patients
per arm would have a >99% power to detect a 30% (SD
20%) difference in LDL-C percent change from baseline to
week 12 between alirocumab and placebo, assuming a 5%
rate of nonevaluable primary end points and using a 2-
sided t test at the 0.05 signiﬁcance level. A hierarchical
testing procedure was used to address multiplicity of
pairwise comparisons versus placebo. The hierarchical
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Figure 1. Least-square mean (SE) percent change from baseline in calcu-
lated low-density lipoprotein cholesterol values in healthy Japanese male
subjects (pharmacodynamic population).
58 The American Journal of Cardiology (www.ajconline.org)testing sequence was continued only when the higher order
test was statistically signiﬁcant at the 5% level to ensure
that overall type I error was controlled at the 5% level. The
primary efﬁcacy analysis was conducted in the modiﬁed
intent-to-treat population, deﬁned as the randomized pop-
ulation with an evaluable primary end point. The efﬁcacy
period was the time from the ﬁrst injection of study drug
up to 21 days after the last injection. Patients in the
modiﬁed intent-to-treat population were analyzed according
to the treatment group allocated by randomization. Percent
change in lipid variables from baseline to week 12 was
analyzed using an ANCOVA model, with treatment group
and randomization strata of atorvastatin dose (<10,
10 mg) as ﬁxed effects and baseline LDL-C value as
covariate. Throughout, each dose of alirocumab was
compared with placebo using appropriate contrasts and
hierarchic procedure, and the 95% adverse event of the
difference versus placebo (not adjusted for multiple com-
parisons) was provided. In case of missing week-12 LDL-C
on-treatment data, the last observation-carried-forward
principle was used. The proportions of patients who ach-
ieved LDL-C values <100 (2.6 mmol/l) or <70 mg/dl
(1.8 mmol/l) at week 12 were analyzed using a stratiﬁed
exact conditional logistic regression model with treatment
group and baseline LDL-C level as effects and atorvastatin
dose (<10, 10 mg) as stratum. The safety population was
deﬁned as the randomized population who received at least
1 dose or partial dose of study treatment. The treatment-
emergent adverse event period was deﬁned as the time
from the ﬁrst dose of study drug up to the last dose plus
70 days.
Results
Thirty-two healthy men were randomized to alirocumab
or placebo in the single-dose study (Supplementary
Figure 2). Their mean (SD) baseline calculated LDL-C
values ranged from 105.3 (12.0) to 130.8 (15.3) mg/dl
(Supplementary Table 2). Single subcutaneous administra-
tion of alirocumab in healthy subjects resulted in a signiﬁ-
cant and sustained mean LDL-C reduction from baseline.
The mean percent reductions in LDL-C from baseline were
from 40% to 60% and were achieved from day 11 until day
22 after treatment for the 100-, 150-, and 250-mg doses and
from day 11 until day 43 for the 300-mg dose (Figure 1). No
deaths, serious adverse events, or other signiﬁcant events
were reported. Orthostatic hypotension developed 30 mi-
nutes after drug administration in a 26-year-old man in the
alirocumab 250-mg dose group; his systolic and diastolic
values returned to normal within 30 minutes. A 39-year-old
man in the placebo group reported fatigue. Both adverse
events were judged to be unrelated to the study drug and
were of mild intensity, and the subjects fully recovered. No
subjects had injection-site reactions. Few potentially clini-
cally signiﬁcant abnormalities in vital signs, laboratory and
electrocardiographic variables were reported, with no
doseeincidence relation, and were not considered to be
clinically signiﬁcant (Supplementary Tables 3 and 4). The
incidences and titers of antidrug antibody were similar
across alirocumab dose groups (Supplementary Table 5).
Serum alirocumab concentrations were similar in antidrugantibody-positive and -negative subjects across alirocumab
dose groups (Supplementary Figure 3).
We screened 162 patients in the multiple-dose study and
100 were randomized to alirocumab or placebo
(Supplementary Figure 4). The patients’ characteristics were
broadly similar across the 4 groups (Table 1). For the primary
modiﬁed intent-to-treat efﬁcacy analysis, least-square mean
(SE) reductions in calculated LDL-C concentrations from
baseline to week 12 were statistically signiﬁcant at all doses
(all p <0.0001; Table 2). A substantial dose-dependent
reduction was achieved in calculated LDL-C in the ﬁrst
2 weeks in the alirocumab groups, which was sustained
through the 12-week treatment period (Figure 2). All the pa-
tients in the 3 alirocumab groups achieved LDL-C<100 mg/
dl (2.6 mmol/l) at week 12, versus 2 (8.0%) patients in the
placebo group. More than 80% patients in each alirocumab
group (n¼ 21, 84.0% in both the 50- and 75-mg groups; n¼
22, 88.0% in the 150-mg group) achieved LDL-C<70 mg/dl
(1.8 mmol/l), versus none in the placebo group. Alirocumab
demonstrated a dose-dependent increase in the number of
patients who achieved a 50% reduction in LDL-C (n ¼ 15,
60.0%; n ¼ 20, 80.0%; n ¼ 23, 92.0%, respectively), versus
none of the patients in the placebo group. The numbers of
patients who displayed at least 1 LDL-C value of <25 mg/dl
(0.7 mmol/l) during the efﬁcacy period were 6 (24.0%) for
alirocumab 50 mg, 10 (40.0%) for 75 mg, and 14 (56.0%) for
150 mg. Alirocumab also resulted in statistically signiﬁcant
decreases in total cholesterol, noneHDL-C, apolipoprotein B
(p <0.0001 at all concentrations), and lipoprotein (a) (all p
<0.01). Triglyceride concentrations were statistically
signiﬁcantly reduced with the 75- and 150-mg doses of alir-
ocumab (p0.02). Treatment-emergent adverse events were
reported in 52.0% of patients on alirocumab 50mg, 48.0% on
alirocumab 75 mg, 64.0% on alirocumab 150 mg, versus
32.0% of patients on placebo (Table 3). Two patients had
serious adverse events: 1 patient in the alirocumab 150-mg
group was diagnosed with breast cancer and discontinued
study treatment prematurely and 1 patient in the placebo
group experienced severe vertigo. Neither event was judged
to be related to the study medication. No deaths were reported
during the study. Injection-site reactions were reported in 7
(9.3%) patients on alirocumab and 1 (4.0%) patient on
Table 1
Baseline characteristics of patients with hypercholesterolemia by randomized treatment
Variable Placebo
(n ¼ 25)
Alirocumab
50 mg Q2W
(n ¼ 25)
Alirocumab
75 mg Q2W
(n ¼ 25)
Alirocumab
150 mg Q2W
(n ¼ 25)
Age (years) 58.6 (9.2) 57.8 (12.3) 56.3 (12.0) 58.2 (8.8)
Women 11 (44%) 16 (64%) 12 (48%) 16 (64%)
Body mass index (kg/m2)* 25.8 (3.2) 24.3 (3.9) 24.5 (3.3) 24.2 (4.4)
Any medical history† 24 (96%) 25 (100%) 23 (92%) 23 (92%)
Hypertension 13 (52%) 9 (36%) 8 (32%) 5 (20%)
Diabetes mellitus (type 2) 4 (16%) 5 (20%) 2 (8%) 5 (20%)
Cerebrovascular disease 2 (8%) 2 (8%) 1 (4%) 0
Peripheral artery disease 1 (4%) 1 (4%) 0 0
Coronary artery disease 0 (0%) 1 (4%) 0 0
Lipid parameter
Low-density lipoprotein cholesterol (Friedewald formula)
(mg/dL)
121.0 (21.1) 122.2 (16.6) 120.9 (16.7) 120.5 (16.2)
Range (minimum : maximum) 89 : 184 95 : 151 98 : 169 93 : 148
Total cholesterol (mg/dL) 203.6 (27.7) 205.2 (19.9) 209.2 (24.3) 212.5 (22.7)
High-density lipoprotein cholesterol (mg/dL) 55.3 (11.2) 58.8 (12.4) 61.1 (15.3) 68.1 (13.5)
Triglycerides, median (quartile 1, quartile 3) (mg/dL) 128.0 (101.5, 156.5) 126.0 (90.5, 136.5) 119.5 (86.5, 182.5) 107.0 (87.0, 124.5)
Nonehigh-density lipoprotein cholesterol (mg/dL) 148.2 (27.0) 146.4 (18.1) 148.0 (23.2) 144.4 (20.7)
Apolipoprotein B (g/L) 1.0 (0.2) 1.0 (0.1) 1.0 (0.2) 1.0 (0.2)
Apolipoprotein A1 (g/L) 1.5 (0.2) 1.5 (0.2) 1.6 (0.3) 1.7 (0.3)
Apolipoprotein B:A1 0.7 (0.2) 0.6 (0.1) 0.6 (0.2) 0.6 (0.1)
Lipoprotein (a), median (quartile 1, quartile 3) (mg/dL) 11.7 (6.9, 26.8) 9.6 (6.7, 23.4) 14.8 (7.5, 28.9) 16.9 (7.3, 39.5)
Other laboratory variables
Glycated hemoglobin (%) 6.1 (0.6) 6.0 (0.8) 5.8 (0.7) 5.9 (0.6)
Glycated hemoglobin
<5.7% 7 (28%) 9 (36%) 13 (52%) 9 (36%)
5.7% to <6.5% 11 (44%) 11 (44%) 9 (36%) 11 (44%)
6.5% 7 (28%) 5 (20%) 3 (12%) 5 (20%)
Plasma glucose, fasting (mg/dL) 109.2 (17.8) 108.8 (20.4) 100.5 (14.6) 104.9 (16.0)
High-sensitivity C-reactive protein (mg/L) 0.8 (0.6) 1.1 (2.5) 1.3 (2.5) 0.5 (0.6)
Data are expressed as mean (SD) or n (%).
Q2W ¼ every 2 weeks.
* Body mass index is the weight in kg divided by the square of the height in m.
† Medical/surgical history other than disease being treated in the study. Patients can be counted in several categories.
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medication in 1 patient on alirocumab 150 mg, leading to
study drug discontinuation, and of mild intensity in the
remaining 7 patients. One patient, on alirocumab 50 mg,
experienced an increase >3 times the upper limit of normal
(ULN) in both alanine aminotransferase and aspartate
aminotransferase. One patient on alirocumab 75 mg had an
increase in alanine phosphatase >1.5 times the ULN, and 3
patients (1 in each alirocumab arm) had creatinine phospho-
kinase elevation >3 (<10) times the ULN. None of the pa-
tients experienced a total bilirubin value>1.5 times the ULN.
Fifteen patients, all in the alirocumab groups, had 2 consec-
utive LDL-C values <25 mg/dl (0.7 mmol/l); of these pa-
tients, 6 had 2 consecutive LDL-C values <15 mg/dl
(0.4 mmol/l). Among the patients with 2 consecutive LDL-C
values <25 mg/dl, adverse events were reported in 1 of 2 on
alirocumab 50-mg group, 2 of 4 on alirocumab 75 mg, and 5
of 9 on alirocumab 150 mg, with no serious adverse events or
discontinuations of study treatment. The rates of adverse
events in this groupwere no different from those in the overall
treated population (Table 3). Additional safety data (vital
signs and electrocardiographic variables) are detailed in
Supplementary Table 6.Discussion
Evidence from randomized trials has shown that the
PCSK9 inhibitor alirocumab, either as monotherapy or in
combination with other LLT, is a highly efﬁcacious treat-
ment for reducing LDL-C in patients at high cardiovascular
risk with hypercholesterolemia, with an acceptable tolera-
bility proﬁle.13e16,18,19,21,22 These studies were, however,
conducted primarily in non-Asian populations. The data
from the present early phase, randomized, placebo-
controlled trials conﬁrm the LDL-Celowering efﬁcacy of
alirocumab in Japanese subjects. Alirocumab reduced LDL-
C concentrations versus placebo in both healthy male sub-
jects and in patients with primary hypercholesterolemia.
In healthy Japanese men, subcutaneous administration of
a single dose of alirocumab (100 to 300 mg) elicited sub-
stantial reductions in LDL-C ranging from 40% to 60%
versus baseline. In patients with primary hypercholester-
olemia, who were on the recommended dose of atorvastatin
with or without other LLT, alirocumab produced dose-
dependent signiﬁcant reductions in LDL-C ranging from
54.8% to 71.7%. The results from these 2 studies in Japa-
nese subjects are in concert with previous ﬁndings,
Table 2
Percent change from baseline to Week 12 in low-density lipoprotein cholesterol and in selected key secondary lipid variables in patients with
hypercholesterolemia
Variable Placebo
(n ¼ 25)
Alirocumab
50 mg
Q2W
(n ¼ 25)
75 mg Q2W
(n ¼ 25)
150 mg Q2W
(n ¼ 25)
Primary endpoint:
Low-density lipoprotein cholesterol (calculated) (modiﬁed intention to treat)
Week 12, mean (SD) (mg/dL)* 116.0 (16.8) 54.4 (16.3) 46.4 (18.5) 35.0 (24.1)
LS mean (SE) change from baseline (%) e2.7 (3.1) e54.8 (3.1) e62.3 (3.1) e71.7 (3.1)
LS mean (SE) difference vs. placebo (%) e e52.2 (4.3) e59.6 (4.3) e69.1 (4.3)
P-value vs. placebo e <0.0001 <0.0001 <0.0001
Secondary endpoints
LS mean (SE) absolute difference in low-density
lipoprotein cholesterol vs. placebo (mg/dL)
e e62.1 (5.0) e69.5 (5.0) e85.8 (3.6)
P-value vs. placebo <0.0001 <0.0001 <0.0001
Total cholesterol
Week 12, mean (SD) (mg/dL)* 200.5 (20.5) 139.7 (22.2) 133.2 (23.3) 123.7 (28.3)
Mean (SD) change from baseline (%) e0.6 (11.3) e31.5 (11.8) e36.4 (7.9) e41.8 (11.4)
LS mean (SE) change from baseline (%) e1.2 (2.1) e31.9 (2.1) e36.3 (2.1) e41.4 (2.1)
LS mean (SE) difference vs. placebo (%) e e30.7 (3.0) e35.1 (3.0) e40.2 (3.0)
P-value vs. placebo e <0.0001 <0.0001 <0.0001
Absolute change from baseline, mean (SD)
(mg/dL)
e3.1 (24.6) e65.5 (26.9) e76.0 (18.5) e88.8 (25.7)
High-density lipoprotein cholesterol
Week 12, mean (SD) (mg/dL)* 56.4 (12.4) 62.3 (13.5) 63.9 (15.0) 68.7 (12.5)
Mean (SD) change from baseline (%) 2.1 (8.0) 6.4 (8.6) 5.7 (12.6) 2.0 (12.5)
LS mean (SE) difference vs. placebo (%) e 5.3 (2.8) 5.2 (2.8) 3.4 (3.0)
P-value vs. placebo e 0.06 0.07 0.25
Absolute change from baseline, mean (SD)
(mg/dL)
1.1 (4.6) 3.6 (5.2) 2.8 (5.9) 0.6 (8.3)
Triglycerides
Week 12, median (quartile 1, quartile 3)
(mg/dL)*
136.0 (105.0, 169.0) 97.0 (70.0, 139.0) 94.0 (75.0, 152.0) 98.0 (72.0, 115.0)
Median (quartile 1, quartile 3), change from
baseline (%)
1.3 (e13.1, 22.5) e21.1 (e28.2, 4.2) e10.7 (e25.0, 6.5) e15.0 (e24.1, 0.0)
Effect size estimate (95% CI) e e17.2 (e29.4 to 2.7) e16.9 (e34.7 to e0.4) e19.4 (e37.5 to e4.7)
P-value vs. placebo e 0.06 0.02 0.006
Absolute change from baseline, median
(quartile 1, quartile 3) (mg/dL)
2.0 (e14.5, 28.5) e19.0 (e32.0, 4.0) e10.0 (e24.5, 4.5) e16.0 (e40.0, 0.0)
Nonehigh-density lipoprotein cholesterol
Week 12, mean (SD) (mg/dL)* 144.2 (20.1) 77.5 (22.0) 69.3 (21.5) 54.9 (23.1)
Mean (SD) change from baseline (%) e1.2 (15.3) e46.4 (16.5) e53.5 (10.5) e62.1 (14.4)
LS mean (SE) change from baseline (%) e0.9 (2.9) e46.3 (2.9) e53.1 (2.9) e62.3 (2.9)
LS mean (SE) difference vs. placebo (%) e e45.4 (4.0) e52.3 (4.0) e61.4 (4.0)
P-value vs. placebo e <0.0001 <0.0001 <0.0001
Absolute change from baseline, mean (SD)
(mg/dL)
e4.0 (24.1) e68.9 (27.4) e78.7 (18.2) e89.5 (24.3)
Apolipoprotein B
Week 12, mean (SD) (g/L)* 1.0 (0.1) 0.5 (0.2) 0.5 (0.2) 0.4 (0.2)
Percent change from baseline, mean (SD) e2.8 (15.1) e43.7 (19.9) e48.9 (12.2) e60.2 (16.5)
LS mean (SE) change from baseline (%) e2.3 (3.3) e43.5 (3.3) e48.6 (3.3) e60.0 (3.3)
LS mean (SE) difference vs. placebo (%) e e41.2 (4.7) e46.3 (4.6) e57.7 (4.6)
P-value vs. placebo e <0.0001 <0.0001 <0.0001
Apolipoprotein A-1
Week 12, mean (SD) (g/L)* 1.5 (0.2) 1.6 (0.2) 1.7 (0.2) 1.7 (0.2)
Mean (SD) change from baseline (%) e1.5 (7.9) 6.1 (6.5) 4.9 (9.7) 3.5 (9.7)
LS mean (SE) difference vs. placebo (%) e 8.1 (2.1) 7.8 (2.1) 7.9 (2.2)
P-value vs. placebo e 0.0002 0.0003 0.0004
Lipoprotein (a)
Week 12, median (quartile 1, quartile 3)
(mg/dL)*
13.6 (4.9, 23.1) 7.3 (2.0, 14.8) 7.1 (4.0, 15.2) 10.0 (2.0, 23.9)
(continued)
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Figure 2. Least-square mean (SE) percent change from baseline in low-density lipoprotein cholesterol values in Japanese patients with primary
hypercholesterolemia.
Table 2
(continued)
Variable Placebo
(n ¼ 25)
Alirocumab
50 mg
Q2W
(n ¼ 25)
75 mg Q2W
(n ¼ 25)
150 mg Q2W
(n ¼ 25)
Median (quartile 1, quartile 3), change from
baseline (%)
e3.7 (e26.2, 8.4) e35.6 (e52.5, e7.5) e40.2 (e62.9, e27.4) e43.3 (e69.4, e14.2)
Effect size estimate (95% CI) e e28.1 (e46.5, e5.5) e37.5 (e55.0, e18.0) e34.1 (e59.1, e8.6)
P-value vs. placebo e 0.0064 0.0003 0.0009
Apolipoprotein B/A-1 ratio
Week 12, mean (SD)* 0.7 (0.2) 0.3 (0.1) 0.3 (0.1) 0.2 (0.1)
LS mean (SE) difference vs. placebo, absolute
change
e e0.3 (0.03) e0.3 (0.03) e0.4 (0.03)
P-value vs. placebo e <0.0001 <0.0001 <0.0001
* Last observation carried forward.
Preventative Cardiology/Efﬁcacy and Safety of Alirocumab in Japanese Subjects 61involving primarily white populations. Speciﬁcally, regi-
mens of 75 to 150 mg Q2W investigated in non-Japanese
patients, in addition to a statin with or without other LLT
or as monotherapy, alirocumab reduced LDL-C by 44% to
58%.13e17 At a dose of 150 mg Q2W, on top of a statin with
or without other LLT, alirocumab reduced LDL-C by 62%
to 73%.18e21 All these data, taken together, show that alir-
ocumab has a consistent and substantial treatment effect
across these populations. The greatest reductions in LDL-C
with alirocumab were achieved within 2 to 3 weeks in the
single-dose study and by 4 weeks in the multiple-dose
study.
Alirocumab also resulted in signiﬁcant reductions in
other lipid variables. The reduction from baseline achieved
for lipoprotein (a) with alirocumab 150 mg Q2W (43.3%) in
the Japanese phase 2 study was greater than that (30.3%)
reported with alirocumab 150 mg Q2W in a pooled analysis
of 3 phase 2 trials in non-Japanese patients with hyper-
cholesterolemia on background lipid-lowering therapy.23
Little is known, however, about the mechanism by which
alirocumab lowers lipoprotein (a) concentrations. Although
the lipoprotein (a) particle is believed to have poor afﬁnity
for the LDL receptor,24 Gaudet et al. proposed that the
further upregulation of the LDL receptor, combined with thevery low concentrations of LDL-C and apolipoprotein B
achieved with alirocumab, permitted the uptake of lipopro-
tein (a) by LDL receptors.23 Of note, the mean baseline
concentration of lipoprotein (a) in patients on alirocumab
150 mg Q2W in our present phase 2 study (16.9 mg/dl) was
substantially lower than that in the pooled study by Gaudet
et al. (30 mg/dl).23 Triglyceride concentrations were also
reduced from baseline in the alirocumab-treated groups in
the phase 2 conducted in Japan. The reduction was moderate
and was consistent with previous phase 3 overseas
studies.13e15,17,20
Alirocumab was generally well tolerated in these Japa-
nese subjects, with no evidence of an excess of adverse
events, serious adverse events, or deaths in either study.
Injection-site reactions were infrequent and mild in in-
tensity. One patient experienced an increase in both alanine
aminotransferase and aspartate aminotransferase, 1 patient
had an increase in alkaline phosphatase, and 3 patients had
elevations in creatinine phosphokinase. All elevations in
laboratory parameters were mild and transient. No drug-
induced liver injury was reported.
We recognize that this is a phase 2 study, in which
hypercholesterolemic patients were at low risk of coronary
artery disease with baseline LDL-C and lipoprotein (a)
Table 3
Treatment-emergent adverse events and laboratory variables in patients with hypercholesterolemia
Variable Placebo
(n ¼ 25)
Alirocumab
50 mg Q2W
(n ¼ 25)
75 mg Q2W
(n ¼ 25)
150 mg Q2W
(n ¼ 25)
Any adverse event 8 (32%) 13 (52%) 12 (48%) 16 (64%)
Serious adverse event 1 (4%) 0 0 1 (4%)
Adverse event leading to death 0 0 0 0
Adverse event leading to discontinuation of study medication 0 0 0 2 (8%)
Primary system organ class (occurring in >1 patient in any group)
Infections and infestations 5 (20%) 8 (32%) 8 (32%) 7 (28%)
Nasopharyngitis 2 (8%) 6 (24%) 6 (24%) 4 (16%)
Cystitis 1 (4%) 0 0 2 (8%)
Musculoskeletal and connective tissue disorders 1 (4%) 4 (16%) 3 (12%) 3 (12%)
Back pain 1 (4%) 2 (8%) 0 1 (4%)
General disorders and administration site conditions 1 (4%) 3 (12%) 2 (8%) 3 (12%)
Injection site reaction 1 (4%) 3 (12%) 2 (8%) 2 (8%)
Injury, poisoning and procedural complications 1 (4%) 0 0 2 (8%)
Ligament sprain 1 (4%) 0 0 2 (8%)
Laboratory parameters
Alanine aminotransferase >3 (<5) xULN 0 1 (4%) 0 0
Aspartate aminotransferase >3 (<5) xULN 0 1 (4%) 0 0
Alkaline phosphatase >1.5xULN 0 0 1 (4%) 0
Creatine phosphokinase >3 (<10) xULN 0 1 (4%) 1 (4%) 1 (4%)
Total bilirubin >1.5 ULN 0 0 0 0
Data are expressed as n (%).
Q2W ¼ every 2 weeks; ULN ¼ upper limit of normal.
62 The American Journal of Cardiology (www.ajconline.org)concentrations close to normal ranges. We did not directly
measure LDL-C values, which would have provided
conﬁrmation of the accuracy of the estimated values. The
small number of study participants and the short durations
limit our ability to assess the safety proﬁle of alirocumab in
Japanese subjects, but our results are consistent with other
studies conducted in primarily Western populations.13e21
The J-LAP study demonstrated unsatisfactory levels of
achievement of LDL-C goals8 in Japanese patients at risk of
coronary artery disease and highlighted the need for more
intensive LLT.11 Shioji et al.25 conducted a comparative
evaluation of rosuvastatin and atorvastatin in Japanese pa-
tients who failed to achieve the Japan Atherosclerosis
Society 2007 goals9 when on atorvastatin therapy. Although
switching to rosuvastatin increased the proportion of pa-
tients who attained the goals (49.3% vs 31.7%, p ¼ 0.010),
half the patients on the more potent statin still had elevated
LDL-C,25 leaving them vulnerable to future cardiovascular
events. These ﬁndings reinforce the need for alternative
therapies, such as the PCSK9 inhibitors,26 to further reduce
lipid levels in statin-treated Japanese patients with dyslipi-
demia. The data obtained in this phase 2 study conducted in
Japanese patients with primary hypercholesterolemia on
atorvastatin are very promising. Alirocumab will be further
evaluated in larger, more diverse patient populations with
different background therapies to conﬁrm its efﬁcacy and
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